State of the Science Summit on Genitourinary Cancers | Conference

Dr. Sonpavde on Agents Under Investigation in PD-L1-Low Bladder Cancer

June 5th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses therapeutic agents under investigation for patients with PD-L1–low bladder cancer.

Dr. Einstein on Immune Therapy in Prostate Cancer

May 30th 2019

David J. Einstein, MD, instructor of medicine at Harvard Medical School, and attending physician of medicine at Beth Israel Deaconess Medical Center, discusses research with immune therapy in prostate cancer.

Dr. McGregor on the Future of Cabozantinib in RCC

May 24th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the future of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).

Dr. Sonpavde on Key Data With Immunotherapy in Metastatic Bladder Cancer

May 17th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses key data with immunotherapy in metastatic bladder cancer.

Dr. McGregor on the Utility of Axitinib/Avelumab in Advanced RCC

May 16th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the data with the combination of axitinib (Inlyta) and avelumab (Bavencio) in advanced renal cell carcinoma (RCC).

Dr. McGregor on Data Evaluating the Link Between Cardiac Complications and ADT in Prostate Cancer

May 15th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the data behind the potential link between cardiac complications and androgen deprivation therapy (ADT) in prostate cancer.

RCC Paradigm Continues to Rapidly Develop With TKI/IO Combos

May 13th 2019

Bradley McGregor, MD, speaks about the various data that have emerged in renal cell carcinoma with combinations of immunotherapy, TKIs, and how he chooses between the available treatments for his patients.

ADT-Associated Cardiac AEs in Prostate Cancer Require Multidisciplinary Care

May 10th 2019

Pei-Chun McGregor, MD, discusses where future research with androgen deprivation therapy-associated adverse events is headed, and called for multidisciplinary care for patients receiving this approach.

Dr. McGregor on Frontline Regimens in Advanced RCC

May 10th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses frontline treatment regimens in advanced renal cell carcinoma (RCC).

Dr. Choudhury on Immunotherapy in Metastatic CRPC

May 10th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses data with immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Rapid Advances Underscore Significance of Patient Selection in Metastatic Prostate Cancer

May 9th 2019

Atish D. Choudhury, MD, PhD, details the advances in metastatic prostate cancer in light of updated analyses from several clinical trials and forthcoming research in the field.

Next Steps in Bladder Cancer Include Chemoimmunotherapy, Targeted Agents, and ADCs

May 9th 2019

Guru Sonpavde, MD, discusses the current use of immunotherapy and the numerous strategies in development in bladder cancer.

Pivotal Studies Pave Way for Nonmetastatic CRPC Treatment

May 8th 2019

Richard (Rick) JaeBong Lee, MD, PhD, discusses the differences between second-generation targeted antiandrogens and highlights potential factors to consider in terms of selection.

Novel Imaging Techniques Emerge in Prostate Cancer

May 6th 2019

David J. Einstein, MD, discusses newer imaging techniques and overall progress in the treatment of patients with nonmetastatic hormone-sensitive prostate cancer.

Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC

May 4th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the clinical implications of the FDA approval of pembrolizumab (Keytruda) and axitinib (Inlyta) in advanced renal cell carcinoma (RCC).

Dr. Einstein on Biochemical Recurrence in Prostate Cancer

May 4th 2019

David J. Einstein, MD, instructor of medicine at Harvard Medical School, and attending physician of medicine at Beth Israel Deaconess Medical Center, discusses biochemical recurrence in patients with prostate cancer.

Dr. Sonpavde on Accelerated Approval of Erdafitinib in Bladder Cancer

May 3rd 2019

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the FDA accelerated approval of erdafitinib (Balversa) in bladder cancer.

Dr. Sonpavde on the Role of Durvalumab in Platinum-Refractory Bladder Cancer

April 24th 2019

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the role of durvalumab in the treatment of patients with platinum-refractory bladder cancer.

Dr. Agarwal on Emerging Immunotherapeutic Combinations in Kidney Cancer

August 3rd 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging immunotherapeutic combinations in kidney cancer.

Dr. Yu on the Future of Castration-Sensitive Prostate Cancer

August 2nd 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the future of castration-sensitive prostate cancer.